



Everest Medicines Limited

雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立之有限公司)

(Stock Code 股份代號: 1952)

NOTIFICATION LETTER 通知信函

Dear Shareholder(s),

1 September 2023

Everest Medicines Limited (the “Company”)

- Notice of Publication of 2023 Interim Report (the “Current Corporate Communication”)

The English and Chinese versions of the Current Corporate Communication are available on the Company’s website at www.everestmedicines.com and are also available on the website of Hong Kong Exchanges and Clearing Limited (“HKEx”) at www.hkexnews.hk. If you have elected to receive Corporate Communications[#] in printed form, the printed form (or forms) of the Current Corporate Communication is (or are) enclosed.

If you would like (i) to receive future Corporate Communications from the Company in printed form instead of in electronic form on the Company’s website (or in electronic form on the Company’s website instead of in printed form) or (ii) to change the language in which you receive Corporate Communications in printed form, please complete the Change Request Form on the reverse side of this letter and sign and return it by post or by hand to the Company c/o the Company’s share registrar in Hong Kong (the “**Hong Kong Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong. If you post your reply in Hong Kong, you may use the mailing label in the Change Request Form and need not affix a stamp on the envelope when returning your Change Request Form. Otherwise, please affix an appropriate stamp. You may also send an email with a scanned copy of the Change Request Form to everestmedicines.ecom@computershare.com.hk. The Change Request Form may also be downloaded from the Company’s website at www.everestmedicines.com or the website of HKEx at www.hkexnews.hk.

If you have elected (or are deemed to have elected) to receive the Current Corporate Communication in electronic form on the Company’s website and for any reason have difficulty in obtaining access to Corporate Communications on the Company’s website, the Company will upon request send the Current Corporate Communication to you in printed form free of charge.

You may at any time by reasonable notice in writing to the Company (sent to the Hong Kong Share Registrar at the above address or by email to everestmedicines.ecom@computershare.com.hk) elect (i) to receive future Corporate Communications from the Company in printed form instead of in electronic form on the Company’s website (or in electronic form on the Company’s website instead of in printed form) or (ii) to change the language in which you receive Corporate Communications in printed form.

Should you have any questions in relation to this letter, please call the telephone hotline of the Hong Kong Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding Hong Kong public holidays.

Yours faithfully,
By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

[#] Corporate communications are all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) full and summary annual and interim financial reports (and all reports and financial statements contained in them), notices of meetings, listing documents, circulars and proxy forms.

各位股東：

**雲頂新耀有限公司（「公司」）
- 2023 年中期報告（「本次公司通訊」）之發佈通知**

本次公司通訊之中、英文版本已上載於公司網站(www.everestmedicines.com)及香港交易及結算所有限公司（「香港交易所」）網站(www.hkexnews.hk)，歡迎查閱。如閣下已選擇收取公司通訊[#]之印刷本，本次公司通訊隨本函附上。

如閣下欲(i)收取公司將來的公司通訊之印刷本，以取代於公司網站登載的電子本(或收取於公司網站登載的電子本，以取代印刷本)或(ii)更改所收取的公司通訊印刷本的語言版本，請閣下填妥在本函背面的變更申請表，並在變更申請表上簽名，然後把變更申請表寄回或親手交回公司之香港證券登記處香港中央證券登記有限公司（「香港證券登記處」），地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。倘若閣下在香港投寄，可使用變更申請表內的郵寄標籤寄回，而毋須在信封上貼上郵票；否則，請貼上適當的郵票。閣下亦可把已填妥之變更申請表的掃描副本電郵至 everestmedicines.ecom@computershare.com.hk。變更申請表可於公司網站(www.everestmedicines.com)或香港交易所網站(www.hkexnews.hk)內下載。

如閣下已選擇(或被視為已同意)收取於公司網站登載的本次公司通訊電子本，惟因任何事故查閱公司通訊上出現困難，只要閣下提出要求，公司將儘快寄上所要求的本次公司通訊的印刷本，費用全免。

閣下可以隨時透過香港證券登記處以書面方式寄送至上述地址或電郵至 everestmedicines.ecom@computershare.com.hk 向公司作合理通知，選擇(i)收取公司將來的公司通訊之印刷本，以取代於公司網站登載的電子本(或收取於公司網站登載的電子本，以取代印刷本)或(ii)更改所收取的公司通訊印刷本的語言版本。

閣下如有任何與本函內容有關的疑問，請致電香港證券登記處電話熱線(852) 2862 8688，辦公時間為星期一至星期五（香港公眾假期除外）上午 9 時正至下午 6 時正。

承董事會命
雲頂新耀有限公司
主席兼執行董事
傅唯
謹啟

2023 年 9 月 1 日

[#]公司通訊乃本公司向其證券持有人發出以供參照或採取行動的任何文件，包括但不限於年度和中期財務報告及其摘要報告（及其中包含的所有報告及財務報表）、會議通告、上市文件、通函及委任代表表格。



Name(s) and address of Shareholder(s):
股東之姓名及地址:

Change Request Form 變更申請表

To: Everest Medicines Limited (the "Company")
(Stock Code: 1952)
c/o Computershare Hong Kong Investor Services Limited
17M Floor, Hopewell Centre, 183 Queen's Road East,
Wan Chai, Hong Kong

致: 雲頂新耀有限公司 (「公司」)
(股份代號: 1952)
經香港中央證券登記有限公司
香港灣仔皇后大道東 183 號
合和中心 17M 樓

I/We would like to receive corporate communications[#] from the Company in the manner indicated below:

本人/我們欲以下列方式收取本公司之公司通訊[#] (「公司通訊」):

(Please mark "X" in ONLY ONE of the following boxes)

(請從下列選擇中, 僅在其中一個空格內劃上「X」號)

to receive all future Corporate Communications in electronic form on the Company's website at www.everestmedicines.com instead of receiving printed copies, and to receive a printed notification letter for the publication of the relevant Corporate Communications on the website of the Company by post; OR
透過本公司網站 www.everestmedicines.com 收取所有將來的公司通訊電子本以代替收取印刷本, 並以郵寄方式收取公司通訊文件已在網上刊發之通知信函印刷本; 或

to receive the printed English version of all future Corporate Communications by post ONLY; OR
僅以郵寄方式收取所有日後公司通訊文件之英文印刷本; 或

to receive the printed Chinese version of all future Corporate Communications by post ONLY; OR
僅以郵寄方式收取所有日後公司通訊文件之中文印刷本; 或

to receive both the printed English and Chinese versions of all future Corporate Communications by post.
以郵寄方式同時收取所有日後公司通訊文件之英文及中文印刷本。

Signature(s)
簽署

Contact Phone Number
聯絡電話號碼

Date
日期

Notes 附註:

- Please complete all your details clearly. Please specify your name and address in ENGLISH BLOCK LETTERS on the top left hand corner of this Change Request Form if you download this form from the web.
請閣下清楚填寫所有資料。倘若閣下從網上下載本申請表格, 請於本表格左上方用英文正楷註明閣下的姓名及地址。
- If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this Change Request Form in order to be valid.
如屬聯名股東, 則本變更申請表須由該名於本公司股東名冊上就聯名持有股份其姓名位列首位的股東簽署, 方為有效。
- Any form with more than one box marked "X", with no box marked "X", with no signature or otherwise incorrectly completed will be void.
如在本表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確, 則本表格將會作廢。
- For the avoidance of doubt, we do not accept any special instructions written on this Change Request Form.
為免疑礙, 任何在本變更申請表上的額外手寫指示, 本公司將不予處理。

[#] Corporate communications are all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) full and summary annual and interim financial reports (and all reports and financial statements contained in them), notices of meetings, listing documents, circulars and proxy forms.
公司通訊乃本公司向其證券持有人發出以供參照或採取行動的任何文件, 包括但不限於年度和中期財務報告及其摘要報告 (及其中包含的所有報告及財務報表)、會議通告、上市文件、通函及委任代表表格。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited
香港中央證券登記有限公司

Freepost No. 簡便回郵號碼: 37
Hong Kong 香港

Please cut the mailing label and stick it on an envelope
to return this Change Request Form to us.
No postage is necessary if posted in Hong Kong.

閣下寄回本變更申請表時, 請將郵寄標籤剪貼於信封上。
如在本港投寄, 閣下無需支付郵費或貼上郵票。

Get in touch with us 與我們聯繫

Send us an enquiry 垂詢
Rate our service 評價
Lodge a complaint 投訴



Contact Us 聯繫我們

www.computershare.com/hk/contact